

Ref: FOI/GS/ID 7370

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

13 April 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to patient treatment with Nivolumab.

You asked:

Q1. In the last 3 months, how many patients have been initiated on the following agents for treatment for melanoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab AND Ipilimumab (combination)*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q2. In the last 3 months, how many patients have been initiated on the following agents for treatment for Renal Cell Carcinoma?*

- a. Nivolumab (monotherapy)*
- b. Nivolumab + Ipilimumab*
- c. Nivolumab + Cabozantinib*
- d. Avelumab + Axitinib*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Q3. In the past 3 months, how many patients have been initiated on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:*

- a. Nivolumab (monotherapy)*
- b. Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)*

**Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Trust response:

- Q1.
- a. 0

b. 3

Q2.

a. 0

b. 0

c. 0

d. 2

Q3.

a. 0

b. 0